Targets › GD2
29 programs from 26 companies in 40 trials: 23 Phase 1, 13 Phase 2, 4 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on GD2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Dinutuximab beta Anti-GD2 monoclonal antibody | GD2 | Phase 3 | Neuroblastoma (NB); Neuroblastoma | Dec 2026 |
| National Cancer Institute (NCI) | Dinutuximab Anti-GD2 monoclonal antibody | GD2 | Phase 3 | Ganglioneuroblastoma, Nodular; Recurrent Neuroblastoma | Mar 2027 |
| New Approaches to Neuroblastoma Therapy Consortium | Dinutuximab Anti-GD2 chimeric monoclonal antibody | GD2 | Phase 2 | Neuroblastoma | Dec 2026 |
| Sun Yat-Sen University Cancer Center | Naxitamab Monoclonal antibody targeting GD2 ganglioside | GD2 | Phase 2 | Neuroblastoma | Dec 2026 |
| Anna Raciborska | Naxitamab Anti-GD2 monoclonal antibody | GD2 | Phase 2 | Ewing Sarcoma | May 2027 |
| Children's Oncology Group | Dinutuximab Anti-GD2 monoclonal antibody | GD2 | Phase 2 | Ganglioneuroblastoma, Nodular; High Risk Neuroblastoma | Sep 2027 |
| Sichuan Cancer Hospital and Research Institute | Nituzumab anti-GD2 monoclonal antibody | GD2 | Phase 2 | Nasopharyngeal Carcinoma | Oct 2027 |
| St. Jude Children's Research Hospital | hu14.18K322A Anti-GD2 monoclonal antibody | GD2 | Phase 2 | Neuroblastoma Recurrent | Feb 2028 |
| Children's Hospital Los Angeles | Dinutuximab anti-GD2 monoclonal antibody | GD2 | Phase 2 | Neuroblastoma | Nov 2028 |
| Tianjin Medical University Cancer Institute and Hospital | Dinutuximab Beta Anti-GD2 monoclonal antibody | GD2 | Phase 2 | Neuroblastoma (NB) | Dec 2028 |
| Memorial Sloan Kettering Cancer Center | DANYELZA anti-GD2 monoclonal antibody | GD2 | Phase 2 | High-risk Neuroblastoma | Jul 2029 |
| Giselle Sholler | Naxitamab Anti-GD2 monoclonal antibody (IgG1) | GD2 | Phase 2 | Neuroblastoma | Sep 2029 |
| Renaissance Pharma | hu14.18K322A monoclonal anti-GD2 antibody | GD2 | Phase 2 | High-Risk Neuroblastoma | Mar 2031 |
| Nationwide Children's Hospital | Dinutuximab Anti-GD2 monoclonal antibody | GD2 | Phase 1 | Relapsed Neuroblastoma | Dec 2026 |
| Emory University | Dinutuximab Anti-GD2 monoclonal antibody | GD2 | Phase 1 | Neuroblastoma | Dec 2026 |
| Bambino Gesù Hospital and Research Institute | GD2-CART01 (iC9-GD2-CAR T-cells) CAR T cell therapy targeting GD2 with inducible Caspase 9 suicide gene | GD2 | Phase 1 | Neuroblastoma; Brain Tumor, Pediatric | Dec 2026 |
| University College, London | hBRCA84D CAR T cells CAR-T cells targeting B7-H3 | B7H3, GD2 | Phase 1 | Neuroblastoma; Diffuse Midline Glioma, H3 K27M-Mutant; Sarcoma | Dec 2026 |
| Beijing Biotech | EB-DART-NK01 Allogeneic dual-target CAR-NK cells (DLL3/CD56, DLL3/GD2, or CD56/GD2) | DLL3, CD56, GD2 | Phase 1 | Small Cell Lung Cancer (SCLC) | Feb 2027 |
| Baylor College of Medicine | C7R-GD2.CART cells Anti-GD2 CAR-T cell therapy | GD2 | Phase 1 | Diffuse Intrinsic Pontine Glioma; Relapsed Neuroblastoma | Feb 2027 |
| Princess Maxima Center for Pediatric Oncology | anti-GD2-800CW anti-GD2 antibody conjugated to near-infrared fluorophore (800CW) for intra-operative dete | GD2 | Phase 1 | Neuroblastoma | Apr 2027 |
| Merck KGaA | M3554 anti-GD2 antibody-drug conjugate | GD2 | Phase 1 | Advanced Solid Tumor | Apr 2027 |
| Beijing Biotech | EB-DTKN-401 Dual-target CSPG4/GD2 CAR-NK cells | CSPG4, GD2 | Phase 1 | Unresectable Melanoma | Jun 2027 |
| Steven DuBois, MD | Naxitamab Recombinant humanized anti-GD2 monoclonal antibody | GD2 | Phase 1 | Neuroblastoma | Jul 2027 |
| M.D. Anderson Cancer Center | Naxitamab Anti-GD2 monoclonal antibody | GD2 | Phase 1 | Metastatic Triple-Negative Breast Cancer | Jul 2028 |
| UNC Lineberger Comprehensive Cancer Center | iC9.GD2.CAR.IL-15 T-cells CAR-T cells targeting GD2 with IL-15 co-expression and inducible caspase-9 safety switch | GD2, IL15 | Phase 1 | Neuroblastoma | May 2030 |
| Princess Maxima Center for Pediatric Oncology | Dinutuximab beta Anti-GD2 monoclonal antibody | GD2 | Phase 1 | Neuroblastoma | Jul 2030 |
| University of Birmingham | Dinutuximab beta Anti-GD2 monoclonal antibody | GD2 | Phase 1 | Relapsed Neuroblastoma | Dec 2030 |
| Chang Gung Memorial Hospital | Dinutuximab-beta Anti-GD2 monoclonal antibody | GD2 | Phase 1 | High Risk Neuroblastoma | Dec 2032 |
| Baylor College of Medicine | iC9-GD2-CAR-VZV-CTLs GD2-targeted CAR-T cells with inducible caspase-9 safety switch and VZV-specificity | GD2 | Phase 1 | Osteosarcoma | Oct 2034 |
Neuroblastoma (14) Relapsed Neuroblastoma (3) Neuroblastoma (NB) (3) Ganglioneuroblastoma, Nodular (2) Small Cell Lung Cancer (SCLC) (2) High Risk Neuroblastoma (2) Brain Tumor, Pediatric (1) Recurrent Neuroblastoma (1) Diffuse Intrinsic Pontine Glioma (1) Neuroblastoma Recurrent (1) Metastatic Triple-Negative Breast Cancer (1) Diffuse Midline Glioma, H3 K27M-Mutant (1)
mixed (12), antibody (7), small molecule (5), other (4), protein or peptide (1)
Baylor College of Medicine (2) Princess Maxima Center for Pediatric Oncology (2) Beijing Biotech (2) Bambino Gesù Hospital and Research Institute (1) Children's Hospital Los Angeles (1) National Cancer Institute (NCI) (1) St. Jude Children's Research Hospital (1) Nationwide Children's Hospital (1) M.D. Anderson Cancer Center (1) University College, London (1) Giselle Sholler (1) Renaissance Pharma (1) Tianjin Medical University Cancer Institute and Hospital (1) Anna Raciborska (1) UNC Lineberger Comprehensive Cancer Center (1) Emory University (1) New Approaches to Neuroblastoma Therapy Consortium (1) Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) Memorial Sloan Kettering Cancer Center (1) Merck KGaA (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.